What this study is
The investigators will conduct two-arm randomized controlled trials (RCTs) comparing effects of UPLIFT vs. enhanced usual care and PACES vs. enhanced usual care, respectively, on quality of life, depressive symptoms and seizures over 12 months in NYU patients with epilepsy.
What's being tested
- UPLIFT
Intervention · BEHAVIORAL
UPLIFT is an 8-week epilepsy self-management programs delivered to small groups of people with epilepsy (PWE) by Webex. UPLIFT is focused on self-management of depressive symptoms. Each weekly session is 1 hour long and is comprised of a check-in period, teaching on the week's topic, group discussion, a skill-building exercise and a home practice assignment.
- PACES
Intervention · BEHAVIORAL
PACES is an 8-week epilepsy self-management programs delivered to small groups of people with epilepsy (PWE) by Webex. PACES focuses on general epilepsy self-management. Each weekly session is 1 hour long and is comprised of a check-in period, teaching on the week's topic, group discussion, a skill-building exercise and a home practice assignment.
- Enhanced Usual Care
Intervention · BEHAVIORAL
Participants receive referrals to local epilepsy support groups.
Study details
- Official title
- Economic Evaluation of Managing Epilepsy Well (MEW) Network Epilepsy Self-Management Programs
- Sponsor
- NYU Langone Health
- Conditions
- Epilepsy
- Enrolling
- 108 people
- Starts
- 2025-09-16
- Est. completion
- 2027-09-29
- Design
- Open-label, randomized, parallel groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Adults (≥18 years)
- English-speaking (UPLIFT and PACES) or Spanish-speaking (UPLIFT only).
- Diagnosed with epilepsy for at least one year
- Able to understand the informed consent and provide consent
- Elevated depressive symptoms - Patient Health Questionnaire-9 (PHQ-9) score ≥10; applies to UPLIFT only
You can't join if
- Severe depressive symptoms (score of ≥20 on PHQ-9)
- Active suicidal ideation (score of ≥1 on PHQ-9 item #9 or otherwise reported during screening)
- Active psychotic disorder (psychiatric diagnosis and/or antipsychotic medications in the electronic health records (EHR)
- Significant cognitive impairment (indicated in the EHR or evident during screening)
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (2)
2 openNYU Langone Health - NYU Langone Hospital-Brooklyn
Brooklyn, New York, United States
RecruitingNYU Langone Health - NYU Comprehensive Epilepsy Center
New York, New York, United States
Recruiting
Study team
Sponsor
NYU Langone Health
Study ID 25-00151
Principal investigator
Tanya Spruill, PhD
NYU Langone Health
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.